Cingulate Inc Quick Ratio (CING) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CING's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth
Cingulate Inc 's Cash & cash equivalent grew by 9.69 % in the Q2 2026 sequentially, while Current Liabilities decreased, this led to improvement in Cingulate Inc 's Quick Ratio to 3.29, above Cingulate Inc average Quick Ratio.
Within Major Pharmaceutical Preparations industry 229 other companies have achieved higher Quick Ratio than Cingulate Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 1283, from total ranking in the first quarter 2026 at 2375.
In a significant development, Cingulate Inc., a Kansas City-based biopharmaceutical company, has recently announced the immediate exercise of a substantial number of Series A and Series B warrants, leading to gross proceeds of $1.86 million. This move showcases the company s commitment to advancing its pipeline of next-generation pharmaceutical products, leveraging its proprietary Precision Timed Release (PTR) drug delivery platform technology. The exercise of these outstanding warrants will result in the purchase of 2,125,000 shares of common stock of Cingulate Inc., originally issued in February 2023, along with the acquisition of an additional 1,062,500 shares. Notably, these warrants, initially priced at $2.00 per share, will now be exercised at a reduced price of $0.585 per share. The shares of common stock being issued upon exercise of the warrants are registered under an effective registration statement on Form S-1 (No. 333-276502), with the closing of the offering anticipated to occur around July 1, 2024, subject to customary closing conditions.
Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market Kansas City, Kan. - Biopharmaceutical company Cingulate Inc. (NASDAQ: CING) has recently made an exciting announcement regarding its latest financial developments. Werth Family Investment Associates, LLC (WFIA), the manager of which is Peter J. Werth, a member of the Cingulate board of directors, has converted $3.3 million of debt and accrued interest into Cingulate equity. The conversion was made at a premium price of $4.785 per share, demonstrating their confidence in the company s future prospects. Cingulate is known for its innovative Precision Timed Release (PTR) drug delivery platform technology, which is utilized to develop and advance a pipeline of next-generation pharmaceutical products. With this recent equity conversion, Cingulate will receive a significant boost in funds, enabling further progress in their research and development efforts.
On the trailing twelve months basis CING Cash & cash equivalent more than doubled by 219.13 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Cingulate Inc 's Quick Ratio to 2.01, above CING average Quick Ratio. Quick Ratio is the average cumulative value over the last four quarters.
Among companies operating within Major Pharmaceutical Preparations industry 431 other companies have achieved higher Quick Ratio than Cingulate Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 2919.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
